title: [Final recommendations to incorporate efalizumab into the clinical practice].
authors.affiliation: Hospital Universitario La Princesa, Universidad Autónoma de Madrid, España. agarcia@edv.es
authors.forename: A
authors.initials: A
authors.lastname: García-Díez
authors.forename: C
authors.initials: C
authors.lastname: Ferrándiz
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011364:Professional Practice; D011565:Psoriasis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; C472181:efalizumab